Health burden in type 2 diabetes and prediabetes in The Maastricht Study.

Autor: Veugen MGJ; Department of Internal Medicine, Maastricht University Medical Centre +, P. Debyelaan 25, P.O. Box 5800, 6202AZ, Maastricht, The Netherlands. marja.veugen@mumc.nl.; CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands. marja.veugen@mumc.nl., Onete VG; Department of Internal Medicine, Maastricht University Medical Centre +, P. Debyelaan 25, P.O. Box 5800, 6202AZ, Maastricht, The Netherlands.; CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands., Henry RMA; Department of Internal Medicine, Maastricht University Medical Centre +, P. Debyelaan 25, P.O. Box 5800, 6202AZ, Maastricht, The Netherlands.; CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands.; Heart and Vascular Centre, Maastricht University Medical Centre +, Maastricht, The Netherlands., Brunner-La Rocca HP; CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands.; Department of Cardiology, Maastricht University Medical Centre +, Maastricht, the Netherlands., Koster A; CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands.; Department of Social Medicine, Maastricht University, Maastricht, The Netherlands., Dagnelie PC; Department of Internal Medicine, Maastricht University Medical Centre +, P. Debyelaan 25, P.O. Box 5800, 6202AZ, Maastricht, The Netherlands.; CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands., Schaper NC; Department of Internal Medicine, Maastricht University Medical Centre +, P. Debyelaan 25, P.O. Box 5800, 6202AZ, Maastricht, The Netherlands.; CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands.; CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands., Sep SJS; Department of Internal Medicine, Maastricht University Medical Centre +, P. Debyelaan 25, P.O. Box 5800, 6202AZ, Maastricht, The Netherlands.; CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands.; Adelante, Centre of Expertise in Rehabilitation and Audiology, Hoensbroek, The Netherlands., van der Kallen CJH; Department of Internal Medicine, Maastricht University Medical Centre +, P. Debyelaan 25, P.O. Box 5800, 6202AZ, Maastricht, The Netherlands.; CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands., van Boxtel MPJ; Department of Psychiatry and Neuropsychology and MHeNS School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands., Reesink KD; CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands.; Department of Biomedical Engineering, Maastricht University Medical Centre +, Maastricht, The Netherlands., Schouten JS; Department of Ophthalmology, Maastricht University Medical Centre +, Maastricht, The Netherlands.; Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands., Savelberg HHCM; Department of Human Movement Sciences, Maastricht University, Maastricht, The Netherlands., Köhler S; Department of Psychiatry and Neuropsychology and MHeNS School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands., Verhey FR; Department of Psychiatry and Neuropsychology and MHeNS School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands., van den Bergh JPW; Department of Family Medicine, Maastricht University, Maastricht, The Netherlands.; Department of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Centre+, Maastricht, The Netherlands.; Department of Internal Medicine, Subdivision of Endocrinology, VieCuri Medical Center, Venlo, The Netherlands., Schram MT; Department of Internal Medicine, Maastricht University Medical Centre +, P. Debyelaan 25, P.O. Box 5800, 6202AZ, Maastricht, The Netherlands.; CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands.; Heart and Vascular Centre, Maastricht University Medical Centre +, Maastricht, The Netherlands., Stehouwer CDA; Department of Internal Medicine, Maastricht University Medical Centre +, P. Debyelaan 25, P.O. Box 5800, 6202AZ, Maastricht, The Netherlands. cda.stehouwer@mumc.nl.; CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands. cda.stehouwer@mumc.nl.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2022 May 05; Vol. 12 (1), pp. 7337. Date of Electronic Publication: 2022 May 05.
DOI: 10.1038/s41598-022-11136-5
Abstrakt: Mortality in type 2 diabetes, is determined not only by classical complications, but also by comorbidities, and is linked to hyperglycaemia and apparent even in prediabetes. We aimed to comprehensively investigate, in a population-based cohort, health burden defined as the presence of comorbidities in addition to classical complications and cardiometabolic risk factors, in not only type 2 diabetes but also prediabetes. Such population-based study has not been performed previously. Extensive phenotyping was performed in 3,410 participants of the population-based Maastricht Study (15.0% prediabetes and 28.6% type 2 diabetes) to assess presence of 17 comorbidities, six classical complications, and ten cardiometabolic risk factors. These were added up into individual and combined sum scores and categorized. Group differences were studied with multinomial regression analyses adjusted for age and sex. Individuals with type 2 diabetes and prediabetes, as compared to normal glucose metabolism (NGM), had greater comorbidities, classical complications, cardiometabolic risk factors and combined sum scores (comorbidities sum score ≥ 3: frequencies (95% CI) 61.5% (57.6;65.4) and 41.2% (36.5;45.9) vs. 25.4% (23.5;27.4), p-trend < 0.001; classical complications ≥ 2 (26.6% (23.1;30.1; P < 0.001 vs. NGM) and 10.1% (7.8;12.7; P = 0.065 vs NGM) vs. 8.0% (6.9;9.3)); cardiometabolic risk factors ≥ 6 (39.7% (35.9;43.4) and 28.5% (24.5;32.6) vs. 14.0% (12.5;15.6); p-trend < 0.001); combined ≥ 8 (66.6% (62.7;70.5) and 48.4% (43.7;53.1) vs. 26.0%(24.1;28.0), p-trend < 0.001). Type 2 diabetes and prediabetes health burden was comparable to respectively 32 and 14 years of ageing. Our population-based study shows, independently of age and sex, a considerable health burden in both type 2 diabetes and prediabetes, which to a substantial extent can be attributed to comorbidities in addition to classical complications and cardiometabolic risk factors. Our findings emphasize the necessity of comorbidities' awareness in (pre)diabetes and for determining the exact role of hyperglycaemia in the occurrence of comorbidities.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje